| scholarly article | Q13442814 |
| P50 | author | Justin M. Balko | Q90244216 |
| P2093 | author name string | Douglas B Johnson | |
| Daniel C Liebler | |||
| Lisa J Zimmerman | |||
| Carlos A Morales-Betanzos | |||
| Hyoungjoo Lee | |||
| Paula I Gonzalez Ericsson | |||
| P2860 | cites work | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. | Q27853331 |
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations | Q28075712 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Differential binding properties of B7-H1 and B7-DC to programmed death-1 | Q28191344 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| T cell exclusion, immune privilege, and the tumor microenvironment | Q28259872 | ||
| Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS) | Q28681060 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy | Q29964482 | ||
| Skyline: an open source document editor for creating and analyzing targeted proteomics experiments | Q30080030 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma | Q39013253 | ||
| VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy | Q39181190 | ||
| A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. | Q40437353 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade | Q41596176 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Abundance-ratio-based semiquantitative analysis of site-specific N-linked glycopeptides present in the plasma of hepatocellular carcinoma patients. | Q43879974 | ||
| Separation of glycopeptides by high performance liquid chromatography | Q72926747 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Q33435967 | ||
| Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry | Q33621574 | ||
| Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 | ||
| VISTA Regulates the Development of Protective Antitumor Immunity | Q33978040 | ||
| Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics | Q34292436 | ||
| Tim-3: an emerging target in the cancer immunotherapy landscape | Q34418718 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics | Q34487045 | ||
| Combination cancer immunotherapy and new immunomodulatory targets | Q34487698 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry | Q34603412 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors | Q34913785 | ||
| Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry | Q35026899 | ||
| Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays | Q35859573 | ||
| PD-1/PD-L1 inhibitors. | Q35893753 | ||
| Assembly Dynamics and Stoichiometry of the Apoptosis Signal-regulating Kinase (ASK) Signalosome in Response to Electrophile Stress | Q35967130 | ||
| Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue | Q36011667 | ||
| Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. | Q36040373 | ||
| Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay | Q36144177 | ||
| Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum | Q36280125 | ||
| Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. | Q36455720 | ||
| Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. | Q36577841 | ||
| Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement | Q37155745 | ||
| Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. | Q37237202 | ||
| Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes | Q37277198 | ||
| Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors | Q37474092 | ||
| An unexpected N-terminal loop in PD-1 dominates binding by nivolumab | Q37637845 | ||
| Clinical blockade of PD1 and LAG3--potential mechanisms of action | Q38298241 | ||
| Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | Q38377528 | ||
| Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential | Q38414485 | ||
| Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. | Q38762520 | ||
| Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society | Q38919358 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stoichiometry | Q213185 |
| glycosylation | Q898365 | ||
| P304 | page(s) | 1705-1717 | |
| P577 | publication date | 2017-05-25 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma | |
| P478 | volume | 16 |
| Q92381156 | Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry |
| Q96577423 | Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer |
| Q92066104 | External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different |
| Q64966271 | Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. |
| Q95925488 | Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation |
| Q90317686 | Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies |
| Q52630284 | Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. |
| Q89450162 | Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy |
| Q97067351 | The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis |
| Q90481320 | The role of proteomics in the age of immunotherapies |
Search more.